Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 (Anbenitamab) Monotherapy or Combination in Metastatic Breast Cancer
NCT04165993Phase 2Active, not recruiting
- Sponsor
- Alphamab Oncology
- Start
- Dec 2019
- Primary completion
- May 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab in breast cancer, sponsored by Alphamab Oncology. Started Dec 2019; status: active, not recruiting.
02
Drugs
anbenitamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04165993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165993.